Treatment Information

Back

Melanoma treatment details. Chemotherapy, Immunotherapy.

University of Schleswig-Holstein, Kiel, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Kiel
Treatments:Chemotherapy, ImmunotherapyHospital:University of Schleswig-Holstein
Drugs:Journal:Link
Date:Jul 2008

Description:

Patients: This phase II study involved 28 patients with metastatic melanoma. There were 16 men and 12 women. The median age was 56, ranging from 42 to 69 years old.

Treatment: Patients were treated with the chemotherapy drug dacarbazine and the immunotherapy interferon-alpha-2a (IFN).

Toxicity: Grade 4 leucopenia was reported in one patient, this got better after the IFN treatment stopped. Grade 3 toxicities included leucopenia/neutropenia, headache, dizziness, fatigue, thrombocytopenia, and high levels of liver enzymes.

Results: The median overall survival was 12.25 months (403 days).

Support: This study was supported by research funds from Roche Pharma AG, which markets IFN as Pegasys.

Correspondence: Dr. Axel Hauschild





Back